Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Bestrophin 1 Antibody (E6-6) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP280593
Description
Bestrophin 1 Monoclonal specifically detects Bestrophin 1 in Human, Porcine, Canine, Primate, Rat (Negative) samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Immunocytochemistry, Dual RNAscope ISH-IHC.Specifications
Bestrophin 1 | |
Monoclonal | |
1 mg/mL | |
Western Blot : 1:1000, Immunohistochemistry reported in scientific literature (PMID 30048622), Immunocytochemistry/Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin reported in scientific literature (PMID 24345323), Immunohistochemistry-Frozen, Immunocytochemistry, Dual RNAscope ISH-IHC | |
ARB, BEST, Best disease, bestrophin 1, bestrophin-1, BMD, TU15B, vitelliform macular dystrophy 2, Vitelliform macular dystrophy protein 2, VMD2RP50 | |
Mouse | |
Protein A or G purified | |
RUO | |
Primary | |
Human, Primate, Porcine reactivity reported in scientific literature (PMID: 11050159). | |
Aliquot and store at -20°C or -80°C. Avoid freeze-thaw cycles. | |
IgG1 κ |
Western Blot, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen), In Situ Hybridization (ISH) | |
E6-6 | |
Unconjugated | |
PBS | |
BEST1 | |
Synthetic peptide conjugated to KLH corresponding to the C-terminus of human Bestrophin 1 (KDHMDPYWALENRDEAHS) [Uniprot: O76090] | |
0.1 mL | |
Neuroscience, Sensory Systems, Vision | |
7439 | |
Human, Pig, Canine, Primate, Rat (Negative) | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction